PERSON
FDA Approves Bimzelx for Expanded Indications: Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Bimzelx, FDA approval, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, IL-17A and IL-17F inhibitor
Athira Pharma Shifts Focus to ALS After Alzheimer’s Setback, Cuts 70% of Workforce
Athira Pharma, Alzheimer’s disease, ALS, layoffs, biotech, neurodegenerative diseases, small molecule therapy
BMS’ KarXT: A Breakthrough in Schizophrenia Treatment with Potential for Alzheimer’s Disease Psychosis
KarXT, schizophrenia, Alzheimer’s disease psychosis, muscarinic receptor agonist, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, novel mechanism of action.
Gilead Partners with Yuhan for $81M HIV Drug Ingredient Supply Deal
Gilead Sciences, Yuhan, HIV drug ingredients, $81M deal, pharmaceutical partnership
Pioneers in Obesity Treatment: Lasker Award Honors Scientists Behind GLP-1 Drugs
Lasker Award, GLP-1 drugs, obesity treatment, Joel Habener, Svetlana Mojsov, Lotte Bjerre Knudsen, medical research, pharmaceuticals.
GC Therapeutics Secures $75 Million Funding for Revolutionary Stem Cell Technology
GC Therapeutics, George Church, stem cell startup, biotech funding, transcription factor screening
Organon Expands Dermatology Portfolio with Acquisition of Dermavant for Up to $1.2 Billion
Organon, Dermavant, Roivant, dermatology, VTAMA cream, tapinarof, plaque psoriasis, atopic dermatitis, acquisition
Ascendis Challenges BioMarin’s Dominance with Promising Achondroplasia Drug Data
Achondroplasia, Ascendis Pharma, BioMarin, TransCon CNP, VOXZOGO, Dwarfism Treatment
Nura Bio Secures $68 Million Funding for Neuroprotective SARM1 Inhibitor Development
Nura Bio, neuroprotective SARM1 inhibitor, $68M funding, pharmaceutical development, neuroprotection
CDMO Serán Secures $200M Investment from Bain Capital to Establish First Commercial Facility
CDMO Serán, Bain Capital, commercial facility, biopharmaceutical manufacturing, investment